In late November, a clinical informatics director at a 400-bed regional medical center sits down with the hospital budget committee. For twelve months, the hospital ran a successful pilot of an artificial intelligence tool designed to flag intracranial hemorrhages on non-contrast head CT scans. The software reduced time-to-treatment by twenty-two minutes and saved five bed-days per week. Yet, as the pilot grant expires, the department faces a familiar obstacle. The clinical value is undisputed, but there is no clear line item in the hospital operating budget to pay for the software licenses.
This scenario plays out across hundreds of health systems annually. For clinical AI developers, building an algorithm with high sensitivity and specificity is only the first hurdle. The more complex challenge is identifying who pays for the technology, and through what mechanism. Historically, healthtech companies sold software as an enterprise expense, forcing clinical champions to compete with physical infrastructure upgrades or nursing staff recruitment. Today, the landscape is shifting. To build a sustainable, scalable business, founders and operators must navigate a complex matrix of reimbursement pathways.
The Hospital Operational Budget Pathway
For early-stage clinical AI products, the default route to market is often the hospital purchasing department. In this model, the health system pays for the software directly out of its own pocket. We define an operational budget as the pool of funds used for the daily running of a hospital, which typically treats software as an overhead expense rather than an income-generating asset.
Selling into the operational budget is difficult because hospital margins are traditionally thin, often hovering between one and two percent. To secure approval, a clinical AI tool must show a clear, measurable return on investment within the first twelve to eighteen months. This return must be financial, not merely clinical. An algorithm that detects sepsis four hours earlier is clinically valuable, but to win operational funding, the developer must prove that this early detection directly translates to a shorter length of stay in the intensive care unit, thereby freeing up staffed beds for profitable elective procedures.
The operational budget pathway is highly sensitive to local hospital dynamics. If a health system is struggling with nurse retention, a tool that reduces nursing documentation time will find favor. Conversely, if the hospital is facing a capital crunch, even a highly effective diagnostic tool may be deferred. Because this pathway depends on individual negotiation and hospital-specific financial health, it is difficult to scale. Relying solely on enterprise purchasing creates long sales cycles, often stretching from nine to eighteen months, with no guarantee of renewal.
Fee-for-Service Reimbursement via CPT Codes
To escape the constraints of hospital overhead budgets, clinical AI developers are increasingly seeking direct reimbursement from commercial insurance plans and government payers. This route relies on the standard medical billing infrastructure. The American Medical Association maintains Current Procedural Terminology codes, which are defined as the standardized language used to report medical, surgical, and diagnostic procedures and services to payers.
For clinical AI, CPT codes are divided into different tiers. Category III codes are temporary codes used for emerging technologies, services, and procedures. These codes allow for data collection and tracking, but they rarely come with a mandated payment rate. Payers typically evaluate Category III codes on a case-by-case basis, and coverage is inconsistent.
To secure predictable revenue, clinical AI platforms must eventually transition to, or utilize, Category I CPT codes. Category I codes are permanent, have a valuation set by the Relative Value Scale Update Committee, and are widely accepted by payers. Achieving a Category I code requires substantial clinical evidence, including peer-reviewed publications showing that the AI improves patient outcomes, as well as evidence of widespread clinical use across multiple geographic regions.
A prominent example of this pathway is in autonomous retinal imaging. When the first autonomous AI system designed to detect diabetic retinopathy in primary care clinics received clearance, it utilized a dedicated Category I code, CPT 92229. This code allows primary care physicians to bill for the AI analysis during a routine clinic visit. By shifting the diagnostic step from an external ophthalmologist to the primary care office, the clinic generates new revenue while improving screening compliance. This alignment of economic incentives has made the autonomous diagnostic pathway one of the most successful commercial models in clinical AI.
Inpatient Innovation via New Technology Add-on Payments
For AI applications designed for acute, inpatient care, standard outpatient CPT codes are not applicable. Inpatient hospital care is reimbursed under a prospective payment system based on diagnosis-related groups. Under this system, the hospital receives a flat fee for an entire patient stay, regardless of the individual resources consumed. If an AI tool costs one hundred dollars per scan, that cost must be absorbed by the flat fee, creating a financial disincentive for hospitals to adopt new technology.
To address this barrier, Medicare administers the New Technology Add-on Payment, which is a temporary program designed to support the adoption of high-cost clinical innovations within the inpatient setting by providing additional reimbursement on top of the standard prospective payment.
To qualify for an add-on payment, a clinical AI technology must meet three strict criteria: it must be relatively new, it must represent a substantial clinical improvement over existing diagnostic or therapeutic options, and its cost must exceed the threshold set by the prospective payment system. If approved, Medicare will pay up to sixty-five percent of the cost of the technology for a limited period, typically two to three years.
This pathway serves as a powerful market-entry mechanism. It allows clinical AI companies to offer their software to inpatient facilities with a subsidized cost structure, reducing the financial risk for early adopters. However, because these payments are temporary, the developer must use the three-year window to collect real-world evidence. This evidence must prove that the technology creates enough clinical efficiency, such as reducing readmission rates or preventing costly complications, to justify the hospital absorbing the software cost into the standard inpatient payment once the add-on funding expires.
Value-Based Care and Risk-Bearing Entities
As the United States healthcare system continues its transition away from fee-for-service medicine, value-based reimbursement is becoming a primary vehicle for clinical AI adoption. We define value-based care as a healthcare delivery model where providers are reimbursed based on patient outcomes and cost reduction rather than the volume of services performed.
In a value-based environment, the traditional billing code framework is less relevant. Risk-bearing entities, such as Accountable Care Organizations, Medicare Advantage plans, and integrated delivery networks, receive a fixed pool of money to manage the health of a specific patient population. If they keep the population healthy and out of the hospital, they keep a portion of the savings. If patient care costs exceed the budget, the organization absorbs the loss.
For clinical AI, this model changes the sales conversation from coding to cost avoidance. An AI tool that screens for early-stage kidney disease or predicts heart failure exacerbations fits perfectly into a value-based framework. Even if there is no specific CPT code to bill for the algorithm, the risk-bearing entity is incentivized to purchase and deploy the software because early detection prevents expensive emergency department visits and hospitalizations. The purchase price of the AI is paid out of the shared savings generated by the clinical intervention. This pathway is highly scalable for preventive and predictive AI tools, but it requires developers to demonstrate a direct link between algorithm alerts and actual clinical intervention protocols.
Designing a Multi-Channel Reimbursement Strategy
Navigating these options requires healthtech founders to make strategic decisions early in the product lifecycle. A common error is building a clinical AI application without a clear understanding of who will pay for it until after receiving regulatory clearance. This omission often leads to a commercial dead end, where the technology is clinically useful but financially unviable.
To avoid this trap, successful platforms employ a dual-track strategy, defined as the simultaneous pursuit of near-term enterprise sales based on cost reduction alongside long-term applications for novel billing codes.
In the near term, a company may target risk-bearing entities and progressive health systems, selling the software as an operational efficiency tool or a tool for clinical risk selection. Simultaneously, the company must invest in the clinical trials and health economics research required to apply for a CPT code or an add-on payment. This dual approach ensures that the company can generate initial commercial traction and gather real-world clinical data while building the long-term, highly defensible moat that direct public and private reimbursement provides.
Ultimately, the clinical AI platforms that scale will be those that treat payment pathways as a core product feature. The technology must not only solve a clinical problem, but it must also fit seamlessly into the existing financial architecture of the healthcare system.
Key Signals
The transition from temporary coding to permanent reimbursement represents the critical inflection point for clinical AI adoption, shifting the technology from a capital expense to a predictable revenue generator.
Successful clinical AI developers are designing clinical trials with health economics endpoints in mind, rather than focusing solely on diagnostic accuracy or algorithm sensitivity.
Value-based care models present the most sustainable long-term pathway for AI tools that prevent disease progression, as these systems naturally reward the long-term cost avoidance that predictive algorithms provide.
